| Year |
Citation |
Score |
| 2023 |
Viikinkoski E, Aittokallio J, Lehto J, Ollila H, Relander A, Vasankari T, Jalkanen J, Gunn J, Jalkanen S, Airaksinen J, Hollmén M, Kiviniemi TO. Prolonged Systemic Inflammatory Response Syndrome After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia. PMID 38220516 DOI: 10.1053/j.jvca.2023.12.017 |
0.397 |
|
| 2023 |
Rannikko JH, Bono P, Hynninen J, Hollmén M. Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments. Cancer Immunology Research. PMID 37922365 DOI: 10.1158/2326-6066.CIR-23-0350 |
0.3 |
|
| 2023 |
Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollmén M, Elo LL, Jalkanen S. Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Critical Care (London, England). 27: 112. PMID 36927455 DOI: 10.1186/s13054-023-04388-8 |
0.398 |
|
| 2023 |
Hua Y, Vella G, Rambow F, Allen E, Martinez AA, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop. Cancer Cell. 41: 226. PMID 36626867 DOI: 10.1016/j.ccell.2022.12.006 |
0.643 |
|
| 2022 |
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop. Cancer Cell. PMID 36423635 DOI: 10.1016/j.ccell.2022.11.002 |
0.696 |
|
| 2022 |
Moisio O, Virta J, Yatkin E, Liljenbäck H, Palani S, Viitanen R, Miner MWG, Oikonen V, Tolvanen T, Vugts DJ, Taimen P, Li XG, Hollmén M, Jalkanen S, Roivainen A. Preclinical Evaluation of a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, Zr-Desferrioxamine-Bexmarilimab, in a Rabbit Model of Renal Fibrosis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 36302655 DOI: 10.2967/jnumed.122.264725 |
0.46 |
|
| 2022 |
Spourquet C, Delcorte O, Lemoine P, Dauguet N, Loriot A, Achouri Y, Hollmén M, Jalkanen S, Huaux F, Lucas S, Meerkeeck PV, Knauf JA, Fagin JA, Dessy C, Mourad M, et al. BRAF Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages. Cancers. 14. PMID 36230610 DOI: 10.3390/cancers14194687 |
0.506 |
|
| 2022 |
Mutka M, Virtakoivu R, Joensuu K, Hollmén M, Heikkilä P. Clever-1 positive macrophages in breast cancer. Breast Cancer Research and Treatment. PMID 35917053 DOI: 10.1007/s10549-022-06683-4 |
0.319 |
|
| 2022 |
Hollmén M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers. Molecular Cancer Therapeutics. PMID 35500016 DOI: 10.1158/1535-7163.MCT-21-0840 |
0.563 |
|
| 2021 |
Viikinkoski E, Jalkanen J, Gunn J, Vasankari T, Lehto J, Valtonen M, Biancari F, Jalkanen S, Airaksinen KEJ, Hollmén M, Kiviniemi TO. Red blood cell transfusion induces abnormal HIF-1α response to cytokine storm after adult cardiac surgery. Scientific Reports. 11: 22230. PMID 34782683 DOI: 10.1038/s41598-021-01695-4 |
0.415 |
|
| 2021 |
Iftakhar-E-Khuda I, Pessia A, Zheng S, Kankainen M, Kontro M, Karikoski M, Laurila J, Gerke H, Tadayon S, Hollmén M, Tang J, Imhof BA, Salmi M, Jalkanen S. Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation. Cellular and Molecular Life Sciences : Cmls. PMID 34719737 DOI: 10.1007/s00018-021-03977-6 |
0.603 |
|
| 2021 |
Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skyttä T, Minchom A, ... ... Hollmen M, et al. Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34078651 DOI: 10.1158/1078-0432.CCR-20-4862 |
0.684 |
|
| 2021 |
Deomic Niittynen S, Liikamaa L, Jalkanen J, Jalkanen S, Savunen T, Gunn J, Anttila V, Virtanen L, Taimen P, Hollmén M, Pan E, Saura E, Malmberg M. Intravenous Interferon-β1a for the Treatment of Ischemia-Reperfusion Injury in Acute Myocardial Infarct in Pigs. The Heart Surgery Forum. 24: E409-E413. PMID 33973512 DOI: 10.1532/hsf.3639 |
0.359 |
|
| 2021 |
Tadayon S, Dunkel J, Takeda A, Eichin D, Virtakoivu R, Elima K, Jalkanen S, Hollmén M. Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1. Frontiers in Immunology. 12: 602122. PMID 33746947 DOI: 10.3389/fimmu.2021.602122 |
0.635 |
|
| 2020 |
Felmerer G, Stylianaki A, Hollmén M, Ströbel P, Stepniewski A, Wang A, Frueh FS, Kim BS, Giovanoli P, Lindenblatt N, Gousopoulos E. Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. Scientific Reports. 10: 10947. PMID 32616854 DOI: 10.1038/S41598-020-67987-3 |
0.323 |
|
| 2020 |
Hollmén M, Figueiredo CR, Jalkanen S. New tools to prevent cancer growth and spread: a 'Clever' approach. British Journal of Cancer. PMID 32595212 DOI: 10.1038/S41416-020-0953-0 |
0.61 |
|
| 2020 |
Jalkanen J, Hollmén M, Jalkanen S. Interferon beta-1a for COVID-19: critical importance of the administration route. Critical Care (London, England). 24: 335. PMID 32532353 DOI: 10.1186/S13054-020-03048-5 |
0.427 |
|
| 2020 |
Jalkanen J, Pettilä V, Huttunen T, Hollmén M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intensive Care Medicine. PMID 32430515 DOI: 10.1007/S00134-020-06086-3 |
0.503 |
|
| 2020 |
Arjonen A, Hakkarainen H, Kononen J, Rantala JK, Hollmén M, Mäkelä R, Virtakoivu R, Kuopio T, Härmä V. Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases Computers & Operations Research. 2020: 1-8. DOI: 10.31487/J.Cor.2020.07.01 |
0.373 |
|
| 2020 |
Bono P, Virtakoivu R, Vaura F, Jaakkola P, Shetty S, Thibault A, Jonge MJAd, Minchom AR, Ma YT, Yap C, Robbrecht D, Pasanen A, Skytta T, Cruz R, Jalkanen M, ... ... Hollmen M, et al. Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results. Journal of Clinical Oncology. 38: 3097-3097. DOI: 10.1200/Jco.2020.38.15_Suppl.3097 |
0.353 |
|
| 2019 |
Hollmén M, Zheng W, Pollard JW. Editorial: Targeting Myeloid Cells to Fight Cancer. Frontiers in Immunology. 10: 2835. PMID 31849994 DOI: 10.3389/Fimmu.2019.02835 |
0.326 |
|
| 2019 |
Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T, Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S. Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. Immunity. PMID 31402260 DOI: 10.1016/J.Immuni.2019.06.027 |
0.742 |
|
| 2019 |
Tadayon S, Dunkel J, Takeda A, Halle O, Karikoski M, Gerke H, Rantakari P, Virtakoivu R, Pabst O, Salmi M, Hollmén M, Jalkanen S. Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology. 4. PMID 30926591 DOI: 10.1126/Sciimmunol.Aat0297 |
0.723 |
|
| 2019 |
Viitala M, Virtakoivu R, Tadayon S, Rannikko J, Jalkanen S, Hollmén M. Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8 T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3289-3303. PMID 30755440 DOI: 10.1158/1078-0432.Ccr-18-3016 |
0.599 |
|
| 2019 |
Jalkanen J, Hollmén M, Maksimow M, Jalkanen S, Hakovirta H. Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine. 114: 74-80. PMID 30442459 DOI: 10.1016/J.Cyto.2018.11.001 |
0.47 |
|
| 2019 |
Toivonen R, Vanhatalo S, Hollmén M, Munukka E, Keskitalo A, Pietilä S, Elo L, Huovinen P, Jalkanen S, Pekkala S. Vascular Adhesion Protein 1 Mediates Gut Microbial Flagellin-Induced Inflammation, Leukocyte Infiltration, and Hepatic Steatosis Scientia Forestalis. 1: 65. DOI: 10.3390/Sci1030065 |
0.302 |
|
| 2019 |
Hollmén M, Virtakoivu R, Jaakkola P, Minchom A, Jalkanen S, Karvonen M, Mandelin J, Koivunen J, Bono P. Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours Annals of Oncology. 30: xi1. DOI: 10.1093/Annonc/Mdz447.001 |
0.591 |
|
| 2019 |
Bono P, Hollmen M, Jaakkola P, Shetty S, Thibault A, de Jonge M, Minchom A, Ma Y, Yap C, Robbrecht D, Pasanen A, Jalkanen S, Cruz R, Pal A, Karvonen M, et al. Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours Annals of Oncology. 30: v865-v866. DOI: 10.1093/Annonc/Mdz394.018 |
0.591 |
|
| 2018 |
Dunkel J, Viitala M, Karikoski M, Rantakari P, Virtakoivu R, Elima K, Hollmén M, Jalkanen S, Salmi M. Enhanced Antibody Production in Clever-1/Stabilin-1-Deficient Mice. Frontiers in Immunology. 9: 2257. PMID 30349531 DOI: 10.3389/Fimmu.2018.02257 |
0.666 |
|
| 2018 |
Munukka E, Ahtiainen JP, Puigbó P, Jalkanen S, Pahkala K, Keskitalo A, Kujala UM, Pietilä S, Hollmén M, Elo L, Huovinen P, D'Auria G, Pekkala S. Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women. Frontiers in Microbiology. 9: 2323. PMID 30337914 DOI: 10.3389/Fmicb.2018.02323 |
0.432 |
|
| 2018 |
Keskitalo A, Munukka E, Toivonen R, Hollmén M, Kainulainen H, Huovinen P, Jalkanen S, Pekkala S. Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. Plos One. 13: e0198262. PMID 29847581 DOI: 10.1371/Journal.Pone.0198262 |
0.464 |
|
| 2018 |
Viitala M, Virtakoivu R, Tadayon S, Jalkanen S, Hollmén M. Abstract 4744: Disruption of Clever-1 in macrophages activates the innate immune response and mediates tumor rejection Cancer Research. 78: 4744-4744. DOI: 10.1158/1538-7445.Am2018-4744 |
0.414 |
|
| 2018 |
Virtakoivu RE, Boström P, Aaltonen R, Koskivuo I, Jalkanen S, Hollmén M. Abstract 4740: CLEVER-1 as a marker to identify breast cancer patients under immunosuppression Cancer Research. 78: 4740-4740. DOI: 10.1158/1538-7445.Am2018-4740 |
0.42 |
|
| 2017 |
Rinne P, Kadiri JJ, Velasco-Delgado M, Nuutinen S, Viitala M, Hollmén M, Rami M, Savontaus E, Steffens S. Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E-/- Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 29284608 DOI: 10.1161/Atvbaha.117.310418 |
0.308 |
|
| 2017 |
Jalkanen J, Hollmén M, Jalkanen S, Hakovirta H. Regulation of CD73 in the development of lower limb atherosclerosis. Purinergic Signalling. 13: 127-134. PMID 27832456 DOI: 10.1007/S11302-016-9545-0 |
0.522 |
|
| 2016 |
Cui J, Hollmén M, Li L, Chen Y, Proulx ST, Reker D, Schneider G, Detmar M. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget. PMID 27894093 DOI: 10.18632/Oncotarget.13537 |
0.4 |
|
| 2016 |
Vaara ST, Hollmén M, Korhonen AM, Maksimow M, Ala-Kokko T, Salmi M, Jalkanen S, Pettilä V. Soluble CD73 in Critically Ill Septic Patients - Data from the Prospective FINNAKI Study. Plos One. 11: e0164420. PMID 27732656 DOI: 10.1371/Journal.Pone.0164420 |
0.646 |
|
| 2016 |
Jalkanen J, Maksimow M, Hollmén M, Jalkanen S, Hakovirta H. Compared to Intermittant Claudication Critical Limb Ischemia Is Associated with Elevated Levels of Cytokines. Plos One. 11: e0162353. PMID 27611073 DOI: 10.1371/Journal.Pone.0162353 |
0.456 |
|
| 2016 |
Christiansen AJ, Dieterich LC, Ohs I, Bachmann SB, Bianchi R, Proulx ST, Hollmén M, Aebischer D, Detmar M. Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation. Oncotarget. 7: 39421-39435. PMID 27270646 DOI: 10.18632/Oncotarget.9820 |
0.434 |
|
| 2016 |
Hollmén M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, Varga Z, Jalkanen S, Detmar M. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology. 5: e1115177. PMID 27141367 DOI: 10.1080/2162402X.2015.1115177 |
0.555 |
|
| 2016 |
Roudnicky F, Hollmén M. Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics Data. 8: 1-3. PMID 27081631 DOI: 10.1016/J.Gdata.2016.02.009 |
0.385 |
|
| 2016 |
Hollmén M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, Varga Z, Jalkanen S, Detmar M. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1115177 |
0.501 |
|
| 2015 |
Hollmén M, Roudnicky F, Karaman S, Detmar M. Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports. 5: 9188. PMID 25776849 DOI: 10.1038/Srep09188 |
0.415 |
|
| 2015 |
Jalkanen J, Yegutkin GG, Hollmén M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circulation Research. 116: 1206-15. PMID 25645301 DOI: 10.1161/Circresaha.116.305715 |
0.506 |
|
| 2015 |
Yegutkin GG, Auvinen K, Rantakari P, Hollmén M, Karikoski M, Grénman R, Elima K, Jalkanen S, Salmi M. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. European Journal of Immunology. 45: 562-73. PMID 25402681 DOI: 10.1002/Eji.201444856 |
0.665 |
|
| 2014 |
Karikoski M, Marttila-Ichihara F, Elima K, Rantakari P, Hollmén M, Kelkka T, Gerke H, Huovinen V, Irjala H, Holmdahl R, Salmi M, Jalkanen S. Clever-1/stabilin-1 controls cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6452-64. PMID 25320356 DOI: 10.1158/1078-0432.Ccr-14-1236 |
0.639 |
|
| 2014 |
He J, Sinues PM, Hollmén M, Li X, Detmar M, Zenobi R. Fingerprinting breast cancer vs. normal mammary cells by mass spectrometric analysis of volatiles. Scientific Reports. 4: 5196. PMID 24903350 DOI: 10.1038/Srep05196 |
0.327 |
|
| 2013 |
Valtcheva N, Primorac A, Jurisic G, Hollmén M, Detmar M. The orphan adhesion G protein-coupled receptor GPR97 regulates migration of lymphatic endothelial cells via the small GTPases RhoA and Cdc42. The Journal of Biological Chemistry. 288: 35736-48. PMID 24178298 DOI: 10.1074/Jbc.M113.512954 |
0.379 |
|
| 2012 |
Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. Proteolytic processing of ErbB4 in breast cancer. Plos One. 7: e39413. PMID 22761786 DOI: 10.1371/Journal.Pone.0039413 |
0.321 |
|
| 2011 |
Hollmén M, Liu P, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. Abstract B187: ErbB4 ectodomain as a biomarker and a potential therapeutic target for breast cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B187 |
0.323 |
|
| 2011 |
Hollmen M, Liu P, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy D, Schoffski P, Elenius K. P5-02-01: ErbB4 Ectodomain as a Biomarker and a Potential Therapeutic Target for Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-02-01 |
0.338 |
|
| 2009 |
Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia (New York, N.Y.). 11: 629-36. PMID 19568408 DOI: 10.1593/Neo.81038 |
0.489 |
|
| 2009 |
Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene. 28: 1309-1319. PMID 19151766 DOI: 10.1038/Onc.2008.481 |
0.339 |
|
| 2009 |
Tvorogov D, Sundvall M, Kurppa K, Hollmén M, Repo S, Johnson MS, Elenius K. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. The Journal of Biological Chemistry. 284: 5582-91. PMID 19098003 DOI: 10.1074/Jbc.M805438200 |
0.311 |
|
| Show low-probability matches. |